参考文献/References:
[1] Almeida JP, Chaichana KL, Rincontorroella J, et al. The
value of extent of resection of glioblastomas: clinical
evidence and current approach [J]. Curr Neurolneurosci,
2015, 15(2): 1-13.
[2] Weller M, Bent MVD, Hopkins K, et al. EANO guideline for
the diagnosis and treatment of anaplastic gliomas and
glioblastoma [J]. Lancet Oncol, 2014, 15(9): e395-e403.
[3] Mukasa A, Wykosky J, Ligon KL, et al. Mutant EGFR is
required for maintenance of glioma growth in vivo, and its
ablation leads to escape from receptor dependence [J].
Proc Natl Acad Sci USA, 2010, 107(6): 2616-2621.
[4] Schuster J, Lai RK, Recht LD, et al. Editor's choice: a phase
Ⅱ, multicenter trial of rindopepimut (CDX-110) in newly
diagnosed glioblastoma: the ACT Ⅲ study [J]. Neuro Oncol,
2015, 17(6):854-861.
[5] Pore N, Liu S, Haaskogan DA, et al. PTEN mutation and
epidermal growth factor receptor activation regulate vascular
endothelial growth factor (VEGF) mRNA expression in
human glioblastoma cells by transactivating the proximal
VEGF promoter [J]. Cancer Res, 2003, 63(1): 236-241.
[6] Luemerson C, Duda DG, Emblem KE, et al. Lessons from
anti-vascular endothelial growth factor and anti-vascular
endothelial growth factor receptor trials in patients with
glioblastoma [J]. J Clin Oncol, 2015, 33(10): 1197-1213.
[7] Sano T, Lin H, Chen X, et al. Differential expression of
MMAC/PTEN in glioblastoma multiforme relationship to
localization and prognosis [J]. Cancer Res, 1999, 59(8):
1820-1824.
[8] Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic
significance of phosphatidylinositol 3-kinase pathway
activation in human gliomas [J]. J Clin Oncol, 2004, 22(10):
1926-1933.
[9] Hu L, Zaloudek CJ, Mills GB, et al. In vivo and in vitro
ovarian carcinoma growth inhibition by a phosphatidy
linositol 3-kinase inhibitor (LY294002).[J]. Clin Cancer
Res, 2000, 6(3): 880-886.
[10] Lopiccolo J, Blumenthal GM, Bernstein W, et al. Targeting
the PI3K/Akt/mTOR pathway: Effective combinations and
clinical considerations [J]. Drug Resist Upda, 2008, 11(1):
32-50.
[11] Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity
of a novel PI3K inhibitor, PX-866, against human glioblas-
toma [J]. Neuro Oncol, 2010, 12(6): 559-569.
[12] Bailey HH, Mahoney MR, Ettinger DS, et al. PhaseⅡ study
of daily oral perifosine in patients with advanced soft tissue
sarcoma [J]. Cancer, 2006, 107(10):2462-2467.
[13] Bagcionder T, Wakimoto H, Anderegg MC, et al. A dual
PI3K/mTOR inhibitor, pi-103, cooperates with stem cell-
delivered trail in experimental glioma models [J]. Cancer
Res, 2011, 71(1): 154-163.
[14] Garlich JR, De P, Dey N, et al. A vascular targeted pan
phosphoinositide 3-kinase inhibitor prodrug, SF1126, with
antitumor and antiangiogenic activity [J]. Cancer Res, 2008,
68(1): 206-215.
[15] Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR
pathways in glioblastoma and implications for combination
therapy with temozolomide [J]. Neuro Oncol, 2011, 13(4):
384-392.
[16] Grier JD, Xiong S, Elizondofraire AC, et al. Tissue-specific
differences of p53 inhibition by Mdm2 and Mdm4 [J]. Cell
Mol Biol, 2006, 26(1): 192-198.
[17] Yamada S, Kanno H, Kawahara N. Trans-membrane peptide
therapy for malignant glioma by use of a peptide derived
from the MDM2 binding site of p53 [J]. J Neuro Oncol,
2012, 109(1):7-14.
[18] Werner L, Huang S, Armstrong EA, et al. Abstract 2610:
AMG 232, a small molecular inhibitor of MDM2 augments
radiation response in human tumors harboring wild-type
p53 [J]. Cancer Res, 2014, 74(19 Supplement): 2610-2610.
[19] Ohgaki H, Kleihues P. Genetic pathways to primary and
secondary glioblastoma [J]. Am J Pathol, 2007, 170(5):
1445-1453.
[20] Gong X, Chio LC, Lallena MJ, et al. Abstract 3104: Molecu-
lar features that determine the sensitivity of cancer cells to
abemaciclib, an inhibitor of CDK4 and CDK6 [J]. Cancer
Res, 2015, 75(15 Supplement): 3104-3104.
[21] Yan H, Parsons D W, Jin G, et al. IDH1 and IDH2 Mutations
in Gliomas[J]. New Engl J Med, 2009, 360(8): 765-773.
[22] Rohle D, Popovicimuller J, Palaskas N, et al. An inhibitor of
mutant IDH1 delays growth and promotes differentiation of
glioma cells [J]. Science, 2013, 340(6132): 626-630.
[23] Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells pro
mote radioresistance by preferential activation of the DNA
damage response [J]. Nature, 2007, 444(7120): 756-760.
[24] Ignatova TN, Kukekov VG, Laywell ED, et al. Human
cortical glial tumors contain neural stem-like cells expre-
ssing astroglial and neuronal markers in vitro [J]. Glia,
2002, 39(3):193-206.
[25] Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade
depletes CD133-positive glioblastoma cells and inhibits
growth of tumor neurospheres and xenografts [J]. Stem Cells,
2010, 28(1): 5-16.
[26] Wang J, Wakeman TP, Lathia JD, et al. Notch promotes
radioresistance of glioma stem cells [J]. Stem Cells, 2009,
28(1): 17-28.
[27] Gilbert CA, Daou M, Moser RP, et al. γ-Secretase inhibi-
tors enhance temozolomide treatment of human gliomas by
inhibiting neurosphere repopulation and xenograft recu-
rrence[J]. Cancer Res, 2010, 70(17): 6870-6879.
相似文献/References:
[1]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(03):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(03):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(03):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波 杨宇焦 张 逵 范润金 张 渊 杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性
癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(03):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚 成于思 王 辉 汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞
增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(03):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林 雨 张 恺 李 帅 杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明 徐成仕 王泽芬 曹长军 李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(03):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生 田道锋 张申起 陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(03):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯 驰 郭双毅 程龙海 罗 杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(03):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]